

(Reference)

Financial Results for FY2025

(April 1, 2025 - March 31, 2026)

&

Outlook for FY2026

(April 1, 2026 - March 31, 2027)

May 14, 2026



(Cautionary Statement)

Statements made in this material with respect to Sumitomo Chemical's current plans, estimates, strategies and beliefs that are not historical facts are forward-looking statements about the future performance of Sumitomo Chemical. These statements are based on management's assumptions and beliefs in light of the information currently available to it, and involve risks and uncertainties. The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in Sumitomo Chemical's markets; demand for, and competitive pricing pressure on, Sumitomo Chemical's products in the marketplace; Sumitomo Chemical's ability to continue to win acceptance for its products in these highly competitive markets; and movements of currency exchange rates.

1. Consolidated Financial Results for FY2025 Ended March 31, 2026

Financial Summary	4
Sales Revenue by Reporting Segment	5
Core Operating Income by Reporting Segment	6
Core Operating Income Analysis by Reporting Segment	7
Consolidated Statement of Financial Position	12
Consolidated Statement of Cash Flows	13

2. Outlook for FY2026 Ending March 31, 2027

Middle East Geopolitics	15
Financial Summary	16
Sales Revenue by Reporting Segment	17
Core Operating Income by Reporting Segment	18
Consolidated Statement of Cash Flows	19

(Reference)

Sales Revenue by Reporting Segment (Quarterly)	21
Core Operating Income by Reporting Segment (Quarterly)	22
Sales Revenue Analysis by Reporting Segment (FY2025)	23
Segment Analysis (FY2026 Forecast)	26
Cost Elements etc.	31
Cost Elements etc. by Reporting Segment	32
Cost Elements etc. by Reporting Segment (Forecast) ..	33
Major Group Companies	34
Crop Protection Product Sales by Region	35
Overseas Sales Revenue	36
Sales Revenue and Profits	37
Interest-bearing Liabilities and D/E Ratio	38
Shareholder Returns	39

1. Consolidated Financial Results for FY2025 Ended March 31, 2026

Financial Summary

	(Billions of yen)			
	FY2025	FY2024	Variance	Variance Ratio
Sales revenue	2,328.5	2,606.3	(277.8)	(10.7)%
Core operating income	208.4	140.5	67.9	48.3%
of which equity-method investments	(43.3)	(62.9)	19.7	-
Total non-recurring items (breakdown below)	(56.6)	52.5	(109.1)	-
Impairment losses	(34.6)	(26.3)	(8.3)	-
Restructuring costs	(26.6)	(23.6)	(3.0)	-
Gains on sales of property, plant and equipment, and intangible assets	1.2	14.3	(13.1)	-
Share of profit of investments accounted for using the equity method (non-recurring factors)	-	83.6	(83.6)	-
Gains on fair value measurement of the residual interest	-	9.4	(9.4)	-
Others	3.4	(4.9)	8.3	-
Operating income	151.7	193.0	(41.3)	(21.4)%
Finance income/expenses (breakdown below)	(35.7)	(134.9)	99.3	-
Loss on foreign currency transactions including gain (loss) on derivatives	0.7	(10.9)	11.7	-
Loss on valuation of investment securities	(13.6)	-	(13.6)	-
Loss on debt waiver for a loan	-	(109.8)	109.8	-
Others	(22.8)	(14.2)	(8.6)	-
Income before taxes	116.1	58.1	58.0	99.8%
Income tax expenses	(0.7)	(15.4)	14.7	-
Net income	115.4	42.7	72.7	170.3%
Net (income) loss attributable to non-controlling interests	(54.5)	(4.1)	(50.4)	-
Net income attributable to owners of the parent	60.9	38.6	22.4	57.9%
ROE	6.4%	4.1%		
Exchange rate (yen/\$)	150.67	152.62		
Naphtha price (yen/kl)	65,200	75,600		
Overseas sales revenue ratio	71.0%	69.9%		


Sales Revenue by Reporting Segment

(Billions of yen)

	FY2025	FY2024	Variance	Variance Ratio	Sales price variance	Shipping volume variance	Foreign currency conversion variance
Agro & Life Solutions	519.3	540.2	(21.0)	(3.9)%	(2.5)	(17.9)	(0.6)
ICT & Mobility Solutions	574.2	607.0	(32.8)	(5.4)%	(10.0)	(17.5)	(5.4)
Advanced Medical Solutions	58.6	62.1	(3.5)	(5.7)%	0.0	(3.8)	0.3
Essential & Green Materials	678.8	899.0	(220.2)	(24.5)%	(43.0)	(176.8)	(0.4)
Sumitomo Pharma *	451.9	398.0	53.9	13.6%	(0.5)	59.8	(5.4)
Others	45.8	99.9	(54.1)	(54.2)%	0.0	(54.1)	0.0
Total	2,328.5	2,606.3	(277.8)	(10.7)%	(56.0)	(210.3)	(11.5)

*The regenerative medicine and cellular therapy CDMO business does not fall under this segment. Due to this, sales revenue differs between this segment and Sumitomo Pharma Co., Ltd.

Variance analysis




Core Operating Income by Reporting Segment

(Billions of yen)

	FY2025	FY2024	Variance	Price variance	Cost variance	Shipping volume variance and other
Agro & Life Solutions	56.3	55.0	1.4	2.5	(1.5)	0.4
ICT & Mobility Solutions	53.0	70.6	(17.5)	(9.0)	(1.5)	(7.0)
Advanced Medical Solutions	2.8	4.0	(1.1)	0.0	(0.5)	(0.6)
Essential & Green Materials	14.4	(58.5)	72.9	15.5	(0.5)	57.9
Sumitomo Pharma *	108.4	35.3	73.1	(0.5)	6.0	67.6
Others & Adjustments	(26.7)	34.2	(60.9)	0.0	0.0	(60.9)
Total	208.4	140.5	67.9	8.5	2.0	57.4

*The regenerative medicine and cellular therapy CDMO business does not fall under this segment. Due to this, core operating income differs between this segment and Sumitomo Pharma Co., Ltd.


Variance analysis



Core Operating Income Analysis by Reporting Segment

Agro & Life Solutions

Total ¥ 56.3 billion ¥ 1.4 billion from FY2024




Price variance	Crop Protection Methionine	Improvement in profit margins
Volume and other variances	Crop Protection	Steady shipments in Japan and overseas

Core Operating Income Analysis by Reporting Segment

ICT & Mobility Solutions

Total ¥ 53.0 billion ¥ (17.5) billion from FY2024




Price variance	Displays	Decline in the selling price of display-related materials
Cost variance	Semiconductors	Increase in R&D expenses
Volume and other variances	Displays	Decrease in shipments of display-related materials Gain on the sale of the large-size LCD polarizing film business
	Semiconductors	Market conditions continue to slowly recover, and shipments have increased

Core Operating Income Analysis by Reporting Segment

Advanced Medical Solutions


Total ¥ 2.8 billion ¥ (1.1) billion from FY2024



Cost variance	Increase in depreciation and amortization
Volume and other variances	Decrease in sales at affiliated companies

Essential & Green Materials


Total ¥ 14.4 billion ¥ 72.9 billion from FY2024



Price variance	Profit margins improved in alumina and synthetic resins
Cost variance	Gain on partial sale of shares in Petro Rabigh Improvement in profitability in investments accounted for using the equity method, due to Petro Rabigh's improved refining margins

Sumitomo Pharma

Total ¥ 108.4 billion ¥ 73.1 billion from FY2024



Price variance	NHI drug price revisions in Japan
Cost variance	Lower fixed costs
Volume and other variances	Gain posted on the partial divestiture of the Asian business Increase in sales of ORGOVYX® (therapeutic agent for advanced prostate cancer) and GEMTESA® (treatment for overactive bladder)

Consolidated Statement of Financial Position

12

(Billions of yen)

	31-Mar-26	31-Mar-25	Variance		31-Mar-26	31-Mar-25	Variance
Current assets	1,507.7	1,583.1	(75.4)	Liabilities	2,168.4	2,365.4	(197.0)
Cash and cash equivalents	208.6	209.8	(1.2)	Trade and other payables	464.4	488.1	(23.7)
Trade and other receivables	608.7	593.8	14.8	Interest-bearing liabilities	1,151.5	1,286.1	(134.7)
Inventories	595.5	625.2	(29.8)	Others	552.5	591.1	(38.6)
Others	95.0	154.2	(59.2)	Equity	1,236.7	1,074.4	162.3
Non-current assets	1,897.3	1,856.7	40.7	Shareholders' equity	744.9	722.3	22.6
Property, plant and equipment	770.7	759.3	11.4	Other components of equity	263.8	178.5	85.3
Goodwill and intangible assets	501.0	497.1	3.9	Non-controlling interests	228.0	173.6	54.4
Others	625.6	600.3	25.3				
Total	3,405.0	3,439.8	(34.7)	Total	3,405.0	3,439.8	(34.7)
				Ratio of equity attributable to owners of the parent to total	29.6%	26.2%	3.4%
				D/E ratio (times)	0.93	1.20	(0.27)

(Billions of yen)

	FY2025	FY2024	Variance
Cash flows from operating activities	234.8	233.0	1.7
Cash flows from investing activities	(74.8)	85.2	(160.1)
Free cash flows	159.9	318.3	(158.3)
Cash flows from financing activities	(199.1)	(300.8)	101.7
Others	15.7	(6.8)	22.5
Increase (decrease) in cash and cash equivalents	(23.5)	10.7	(34.1)
Cash and cash equivalents at the end of the period	208.6	209.8	(1.2)

2. Outlook for FY2026 Ending March 31, 2027

➤ Current situation

Raw materials procurement

- Naphtha: Continue to work toward stable supply. Visibility into requirements into June.
- Others: Secured requirements for current production plans, although there are some risks.

Utilization trends

- Japan P&P: Operations continue based on availability of inventory and raw materials procurement environment
- Singapore P&P: Issued FM declaration in March 2026 Closely monitoring impacts given potential for supply constraints
- Other: No major impediments to operations currently, despite the existence of risks

Sales trends

- Higher raw material costs: Advancing rationalization and efficiencies while working to appropriately reflect cost inflation into prices
- Demand: No observations of substantial decline in demand due to rising prices

(Billions of yen)

	FY2026 forecast	FY2025	Variance	Variance Ratio
Sales revenue	2,360.0	2,328.5	31.5	1.4%
Core operating income	215.0	208.4	6.6	3.2%
Net income attributable to owners of the parent	70.0	60.9	9.1	14.9%
ROE	6.8%	6.4%		
Exchange rate (yen/\$)	155.00	150.67		
Naphtha price (yen/kl)	92,000	65,200		
Cash dividends (yen)	Interim dividend	8.00	6.00	
	Year-end dividend	8.00	7.50	
	Annual dividend	16.00	13.50	

Sales Revenue by Reporting Segment

(Billions of yen)

	FY2026 (Forecast)	FY2025	Variance	Variance Ratio	Sales price variance	Shipping volume variance	Foreign currency conversion variance
Agro & Life Solutions	560.0	519.3	40.7	7.8%	(2.0)	43.6	(0.8)
ICT & Mobility Solutions	590.0	574.2	15.8	2.8%	(3.0)	13.4	5.4
Advanced Medical Solutions	60.0	58.6	1.4	2.4%	1.0	0.4	0.0
Essential & Green Materials	560.0	678.8	(118.8)	(17.5)%	10.5	(134.1)	4.8
Sumitomo Pharma	540.0	451.9	88.1	19.5%	(3.0)	78.9	12.2
Others	50.0	45.8	4.2	9.3%	0.0	4.2	0.0
Total	2,360.0	2,328.5	31.5	1.4%	3.5	6.4	21.6

Variance analysis




Core Operating Income by Reporting Segment

(Billions of yen)

	FY2026 (Forecast)	FY2025	Variance	Price variance	Cost variance	Shipping volume variance and other
Agro & Life Solutions	65.0	56.3	8.7	2.0	(3.0)	9.7
ICT & Mobility Solutions	55.0	53.0	2.0	(3.5)	(5.5)	11.0
Advanced Medical Solutions	3.0	2.8	0.2	1.0	(1.5)	0.7
Essential & Green Materials	20.0	14.4	5.6	0.5	5.0	0.1
Sumitomo Pharma	94.0	108.4	(14.4)	(3.0)	1.5	(12.9)
Others	(22.0)	(26.7)	4.7	0.0	0.0	4.7
Total	215.0	208.4	6.6	(3.0)	(3.5)	13.1

Variance analysis



(Billions of yen)

	FY2026 (Forecast)	FY2025	Variance
Cash flows from operating activities	210.0	234.8	(24.8)
Cash flows from investing activities	(150.0)	(74.8)	(75.2)
Free cash flows	60.0	159.9	(99.9)
Cash flows from financing activities	0.0	(199.1)	199.1
Effect of exchange rate changes on cash and cash equivalents	0.0	15.7	(15.7)
Net change in cash and cash equivalents	60.0	(23.5)	83.5
Interest-bearing debt balance	1,120.0	1,151.5	(31.5)

(Reference)

Sales Revenue by Reporting Segment (Quarterly)

21

(Billions of yen)

	FY2024				FY2025				FY2026
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Total Forecast
Agro & Life Solutions	106.4	118.6	138.1	177.1	96.9	116.1	133.9	172.4	560.0
ICT & Mobility Solutions	152.7	154.8	153.8	145.8	137.4	146.1	148.3	142.4	590.0
Advanced Medical Solutions	13.2	13.6	14.0	21.4	9.1	12.1	14.5	23.0	60.0
Essential & Green Materials	225.0	226.0	222.0	226.1	165.4	163.8	181.8	167.8	560.0
Sumitomo Pharma	90.6	89.8	112.4	105.2	107.4	118.7	120.3	105.5	540.0
Others	24.3	26.5	23.2	25.8	10.0	12.6	12.1	11.1	50.0
Total	612.1	629.3	663.4	701.4	526.1	569.3	610.9	622.2	2,360.0


Core Operating Income by Reporting Segment (Quarterly)

22

(Billions of yen)

	FY2024				FY2025				FY2026
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Total Forecast
Agro & Life Solutions	4.9	9.2	5.4	35.5	2.2	9.0	16.9	28.2	65.0
ICT & Mobility Solutions	21.2	22.4	16.1	10.8	18.4	14.7	13.4	6.5	55.0
Advanced Medical Solutions	0.5	(0.1)	0.8	2.8	(1.0)	(0.4)	1.7	2.5	3.0
Essential & Green Materials	(19.6)	(15.2)	(9.6)	(14.1)	(5.5)	(13.1)	38.4	(5.3)	20.0
Sumitomo Pharma	0.9	2.1	21.4	10.9	21.0	76.3	13.9	(2.8)	94.0
Others & Adjustments	(2.2)	5.3	(3.6)	34.6	(7.4)	(5.5)	(6.2)	(7.6)	(22.0)
Total	5.7	23.8	30.6	80.5	27.7	81.0	78.1	21.5	215.0


Agro & Life Solutions



Total ¥ 519.3 billion ¥ (21.0) billion from FY2024

Price	(2.5)	□ Decline in the selling price for crop protection products in South America
Volume	(17.9)	□ Decrease in shipments of methionine □ Decrease in shipments of crop protection products mainly in South America
Foreign exchange	(0.6)	

ICT & Mobility Solutions



Total ¥ 574.2 billion ¥ (32.8) billion from FY2024

Price	(10.0)	□ Decline in the selling price of display-related materials
Volume	(17.5)	□ Decrease in shipments of display-related materials □ Recovery in shipments of processing materials for semiconductors
Foreign exchange	(5.4)	

Advanced Medical Solutions



Total ¥ 58.6 billion ¥ (3.5) billion from FY2024


Price 0.0

Volume (3.8)

Foreign exchange 0.3

- Shipment cycle of pharmaceutical chemicals

Essential & Green Materials



Total ¥ 678.8 billion ¥ (220.2) billion from FY2024


Price (43.0)

Volume (176.8)

Foreign exchange (0.4)

- Decline in market prices for naphtha and products
- Exit from the aluminum business etc.
- Decrease in shipments from sales subsidiaries due to periodic shutdown maintenance at Petro Rabigh

Sumitomo Pharma




Total ¥ 451.9 billion ¥ 53.9 billion from FY2024

Price (0.5) □ NHI drug price revisions in Japan

Volume 59.8 □ Increase in sales of ORGOVYX® and GEMTESA®

Foreign exchange (5.4)

Sales Revenue



Total ¥ 560.0 billion ¥ 40.7 billion from FY2025

Sales price

(2.0)

- Lower market prices for methionine

Volume


43.6

- Increase in overseas shipments of crop protection products

Foreign exchange

(0.8)

Core Operating Income



Total ¥ 65.0 billion ¥ 8.7 billion from FY2025

Price variance

2.0

- Improvement in overseas market conditions for crop protection products
- Deterioration in trading conditions for methionine

Cost variance

(3.0)

Volume and other

9.7

- Increase in overseas shipments of crop protection products

Sales Revenue



Total ¥ 590.0 billion ¥ 15.8 billion from FY2025

Sales price
(3.0)

- Decline in the selling price of display-related materials


Volume
13.4

- Increase in shipments of processing materials for semiconductors

Foreign exchange
5.4

- Decrease in shipments due to the sale of the large-size LCD polarizing film business

Core Operating Income



Total ¥ 55.0 billion ¥ 2.0 billion from FY2025

Price variance
(3.5)

- Decline in the selling price of display-related materials

Cost variance
(5.5)

- Increase in depreciation and amortization related to processing materials for semiconductors

Volume and other
11.0

- Increase in shipments of processing materials for semiconductors

Sales Revenue



Total ¥ 60.0 billion ¥ 1.4 billion from FY2025

Sales price

1.0

Volume

0.4

□ Increase in shipments from affiliated companies

Foreign exchange

0.0

Core Operating Income



Total ¥ 3.0 billion ¥ 0.2 billion from FY2025

Price variance

1.0

Cost variance


(1.5)

□ Increase in fixed costs

Volume and other

0.7

Sales Revenue



Total ¥ 560.0 billion ¥ (118.8) billion from FY2025

Sales price

10.5

- Increase in the price of naphtha

Volume

(134.1)

- Termination of resale of Petro Rabigh products

Foreign exchange

4.8

Core Operating Income



Total ¥ 20.0 billion ¥ 5.6 billion from FY2025

Price variance

0.5

Cost variance

5.0

Volume and other

0.1

- Lower depreciation expenses due to impairment losses recorded in the previous fiscal year
- Absence of gain on the partial sale of shares in Petro Rabigh
- Improvement in profitability in investments accounted for using the equity method at Petro Rabigh

Sales Revenue



Total ¥ 540.0 billion ¥ 88.1 billion from FY2025

Sales price
(3.0)

- NHI drug price revisions in Japan

Volume
78.9

- Increase in sales of ORGOVYX® and GEMTESA®

Foreign exchange
12.2

Core Operating Income



Total ¥ 94.0 billion ¥ (14.4) billion from FY2025

Price variance
(3.0)

- NHI drug price revisions in Japan

Cost variance
1.5

- Absence of gain posted on the partial divestiture of the Asian business

Volume and other
(12.9)

- Increase in sales of ORGOVYX® and GEMTESA®

(Billions of yen)

	FY2025	FY2024	Variance	FY2026 (Forecast)
Capital Expenditures	121.6	131.7	(10.2)	119.0
Depreciation and Amortization	121.1	131.6	(10.5)	121.0
Research & Development Expenses	144.7	145.2	(0.5)	161.0
Number of Employees (as of March 31)	27,491	29,279	(1,788)	27,700

(Billions of yen)

	Capital Expenditures		Depreciation & Amortization		R&D Expenses	
	FY2025	FY2024	FY2025	FY2024	FY2025	FY2024
Agro & Life Solutions	15.8	20.1	21.2	21.0	31.6	30.6
ICT & Mobility Solutions	53.0	49.2	33.7	34.2	33.4	31.4
Advanced Medical Solutions	9.6	13.0	7.8	7.7	3.8	3.4
Essential & Green Materials	18.2	26.3	19.2	22.8	8.4	9.9
Sumitomo Pharma	8.1	11.5	20.8	24.9	44.0	43.4
Others	16.9	11.6	18.4	21.1	23.5	26.5
Total	121.6	131.7	121.1	131.6	144.7	145.2

(Billions of yen)

	Capital Expenditures		Depreciation & Amortization		R&D Expenses	
	FY2026 (Forecast)	FY2025	FY2026 (Forecast)	FY2025	FY2026 (Forecast)	FY2025
Agro & Life Solutions	18.0	15.8	20.5	21.2	35.0	31.6
ICT & Mobility Solutions	41.5	53.0	41.5	33.7	37.5	33.4
Advanced Medical Solutions	10.5	9.6	8.0	7.8	4.0	3.8
Essential & Green Materials	29.5	18.2	14.0	19.2	6.5	8.4
Sumitomo Pharma	10.0	8.1	20.5	20.8	51.0	44.0
Others	9.5	16.9	16.5	18.4	27.0	23.5
Total	119.0	121.6	121.0	121.1	161.0	144.7


Company	Sales Revenue		Profit
	FY2025	FY2024	
The Polyolefin Company (Singapore) <small>(Millions of USD)</small>	726	843	↗ Improvement in profit margins
PCS <small>(Millions of USD)</small>	2,087	2,389	↘ Deterioration in profit margins
Rabigh Refining and Petrochemical Company <small>(Millions of SAR)</small>	35,008	39,349	↗ Improvement in petroleum refining margins
Dongwoo Fine-Chem <small>(Billions of KRW)</small>	2,039.9	2,089.3	↘ Decrease in sales volume of display-related materials and deterioration in profit margins
Sumitomo Chemical Brasil Indústria Química S.A. <small>(Millions of BRL)</small>	3,485	4,103	↗ Improvement in market conditions
Valent North America and subsidiaries <small>(Millions of USD)</small>	950	942	↗ Improvement in market conditions

※Valent North America has changed its company name to Sumitomo Biorational Company.

Crop Protection Product Sales by Region


(Billions of yen)

	FY2024	FY2025	Variance	Reasons for Change
Japan	78.5	86.2	7.7	• Increase in sales volume due to a rise in outbreaks of insects that cause damage to crops, etc.
North America	94.9	93.3	(1.6)	
Central & South America	130.4	113.3	(17.1)	• Decline in shipments due to unfavorable weather conditions, etc.
Asia (Including India)	69.0	66.8	(2.2)	
Europe & Others	34.7	43.5	8.8	• Foreign currency conversion variance (JPY weakening against the EUR) • Increase in sales volume due to expanded uses of certain products, etc.
Total	407.5	403.1	(4.4)	



Overseas Sales Revenue Ratio

71.0%



Overseas Sales Revenue Ratio


69.9%

Sales Revenue

(¥ billion)


Profit

(¥ billion)



Interest-bearing Liabilities

(¥ billion)




D/E Ratio

(Times)



Dividends per share

Net income attributable to owners of the parent



Payout Ratio(%)

30.5

89.9

53.3

24.2

421.2

—

38.2

36.3

37.7

Interim dividends

Year-end dividends

Net income attributable to owners of the parent